© 2020, The Author(s). In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline multigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.
Guillén-Ponce, C., Lastra, E., Lorenzo-Lorenzo, I., Martín Gómez, T., Morales Chamorro, R., Sánchez-Heras, A. B., Serrano, R., Soriano Rodríguez, M. C., Soto, J. L., & Robles, L. (2020). SEOM clinical guideline on hereditary colorectal cancer (2019). Clinical and Translational Oncology, 201-212. https://doi.org/10.1007/s12094-019-02272-y